Pharmacology & Biotechnology
- Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy
Vamorolone is a first-in-class dissociative drug that selectively targets the glucocorticoid receptor to safely treat chronic inflammation and the mineralocorticoid receptor to treat cardiomyopathy, providing efficacy with improved safety in mouse models of Duchenne muscular dystrophy.